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Five mondonal antibodies (L15, L20, L23, L34, and L61) against human recombinant interleukin-2 were tested for 
their effects on the interleukin-2 bioactivity and binding. Four of these monoclonal antibodies, L 15, L20. L34, and L61, 
which had neutralizing activity, completely blocked interleukin-2 binding to the high-affinity receptor. On the other hand, 
L23, which had a very weak neutraliaing activity, blocked intcrleukin-2 binding to the low-affinity receptor. These results 
suggest that there are at least two distinct binding sites on the interleukin-2 molecule; those for the high-affinity receptor 
and those for the low&inity receptor. These monoclonal antibodies hould be useful tools in the study of the interaction 
between interleukin-2 and interleukin-2 receptor. 
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1. INTRODUCTION 
Interleukin-2 (IL-2) plays pivotal roles in the im- 
mune system [l-3]. IL-2 induces proliferation and 
activation of T cells. It also induces growth and 
differentiation of B cells [4]. Cumulative evidence 
supports the idea that IL-2 exerts these effects 
through interaction with a specific receptor present 
on the surface membrane of responsive cells. IL-2 
receptor (IL3R) has been detected in high- and 
low-affinity forms and only the high-affinity 
receptor could transduce the signals of IL-2 [5]. 
Tat antigen (p55) was initially identified as the 
IL-2R using anti Tat monoclonal antibody [6]. 
The gene for Tat protein has been cloned [7,8] but 
on transfection induced only the expression of low- 
affinity IL-2R [9]. Recently, a novel IL-2R, p70/75 
was detected by affinity cross-linking study 
[ 1 O- 131. The p70/75 IL-2R identified on LGL cells 
by itself has an intermediate affinity for IL-2 but 
is capable of transducing the signal of IL-2. It is 
assumed that the high-affinity state is induced by 
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the complex formation between ~55 and p70/75, 
but nothing yet is known about the nature of 
~70175, except for the behavior of the cross-linked 
protein on sodium dodecyl sulfate polyacrylamide 
gel. Neither is anything known about the 
mechanism of complex formation or interaction of 
IL-2 with these receptor subunits. 
Monoclonal antibodies (mAbs) to IL-2 should 
be useful tools for studying the relationship be- 
tween the structure and function of IL-2. We 
previously established mouse hybridoma cell lines 
producing mAbs against recombinant human IL-2 
(rIL-2) [14]. In this report, we show that IL-2 bind 
these receptor subunits through different binding 
sites on the IL-2 molecule and that the high- and 
low-affinity binding sites on the IL-2 molecule can 
be differentially recognized by these mAbs. 
2. MATERIALS AND METHODS 
2.1. Cell culture condition 
The IL-2 dependent murine CTLL-2 was kindly donated by 
Professor Kumagai of Tohoku University. CTLL-2 was main- 
tained in RPM1 1640 medium (Nissui & Co.) supplemented with 
10% fetal calf serum (Boehringer Mannheim), 4 mM L- 
glutamine, 1.4 mM sodium pyruvate, 50 /cM 2-mercapto- 
ethanol, 10 mM Hepes, pH 6.8, and 100 U/ml rIL-2 (Biogen). 
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Cultures were maintained in a humidified incubator at 37OC 
with an atmosphere of 5% CO2 in air. 
2.2. mAbs 
Five mouse mAbs, Ll5, L20, L23, L34, and L61 are directed 
against rIL-2 [14]. They were purified from ascitic fluid by pro- 
tein A agarose affinity chromatography (BioRad, MAPS II 
kit). Affinity constants of purified mAbs against rIL-2 were 
calculated from Scatchard plots using [iz51]IL-2 as described 
u41. 
2.3. Bioassay of mAbs 
mAbs were assayed for their activity to neutralize the pro- 
liferative effect of rIL-2 on IL-2 dependent murine T cell line, 
CTLL-2 as described elsewhere [IS]. The cells were washed with 
RPM1 1640 medium containing 10% fetal calf serum, 50pM 
2-mercaptoethanol, and 1.4 mM sodium pyruvate followed by 
incubation for 16 h and seeded into 96well microtiter plates 
(104 cells/well). Serially diluted mAbs and a constant level of 
rIL-2 (4 U/ml, i.e. 25 PM) were added in a total volume of 
200~1. After 20 h incubation at 37”C, [3H]thymidine (Amer- 
sham, 0.5 &i/well) was added and pulse-labeled for 4 h. The 
cells were collected on glass fiber filters, washed with water, and 
counted for radioactivity in a liquid scintillation counter. The 
extent of [3H]thymidine incorporation was expressed as the 
percentage of the count obtained in the absence of the mAbs. 
2.4. IL-2 binding assay 
The binding of radioiodinated IL-2 to CTLL-2 cells was 
measured according to the methods described by Robb et al. 
[5]. Before the binding experiment, prebound IL-2 was removed 
by incubating the cells in 10 mM sodium citrate, pH 4.0, con- 
taining 0.14 M NaCl for 20 s followed by centrifugation at 3000 
x g for 1 min. After washing, the cells (2 x 106) were 
resuspended in RPM1 1640 medium containing 10% fetal calf 
serum, 4 mM L-glutamine, 1.4 mM sodium pyruvate, 50pM 
2-mercaptoethanol, and 10 mM Hepes, pH 6.8. Serial dilutions 
of 1251-labeled IL-2 (Amersham) were added and incubated for 
1 h at 4OC in a total volume of 200~1. Next, cells were cen- 
trifuged for 5 min at 1000 x g and resuspended in 100 ,ul of the 
same medium. Residual unbound radioactivity was removed by 
centrifugation for 5 min at 1000 x g through a 300-~1 layer of 
a mixture of 20% olive and 80% di-n-butyl phthalate. The tips 
of the tubes containing the cell pellets were cut off, placed in 
4-ml polystyrene tubes, and counted for radioactivity in a gam- 
ma counter. Non-specific binding was determined in the 
presence of a 200-fold excess of cold IL-2. 
3. RESULTS AND DISCUSSION 
A series of hybridoma cell lines which produce 
mAbs against rIL-2 were established previously 
[ 141. mAbs were assayed for their inhibitory activi- 
ty on IL-2-dependent cellular proliferation. Titra- 
tion curves of chromatographically purified mAbs 
are shown in fig.1. The ability of mAb to 
neutralize the IL-2 activity is in the order of L61 > 
L15, L20, L34 > L23. Next, the effect of mAbs on 
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Fig.1. Neutralizing activity of mAbs against rIL-2. Serial 
dilutions of mAbs (0, L15; n , L20; o, L23; A , L34; *, L61) 
were added to the bioassay medium containing CTLL-2 (104 
cells/well) and rIL-2 (4 U/ml). 
the binding of IL-2 to IL-2R was studied. Ex- 
periments were carried out under conditions per- 
mitting the binding of IL-2 to only high-affinity 
sites [5,10] (fig.2). The ability of mAb to block the 
IL-2 binding to the IL-2R is in the order of L61 > 
L15, L20, L34 > L23. These results suggest hat 
the neutralizing activity of the mAbs correlated 
directly with their inhibitory activity on high- 
affinity binding. The difference of neutralizing ac- 
tivity of these mAbs could then be ascribed to the 
difference of their affinity to IL-2 or to the dif- 
ference of recognition sites on the IL-2 molecule. 
Table 1 shows the affinity constants of these mAbs 
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Fig.2. Inhibition activity of mAbs on IL-2 binding to CTLL-2. 
Serial dilutions of mAbs (0, L15; W, L20; 0, L23; A, L34; 
+ , L61) were preincubated with 50 pM [“‘I]IL-2 for 1 h at 4°C 
and then the reaction mixture was added to the binding assay 
medium containing CTLL-2 (2 x lo6 cells/tube). 
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Table 1 
Affinity constants of mAbs for rIL-2 
mAbs 
L15 
L20 
L23 
L34 
L61 
Affinity constant (KJ (M-l) 
4.99 x 10s 
1.61 x 10s 
1.60 x lo* 
3.19 x 10’ 
2.14 x 10’ 
for rIL-2. Most of these mAbs exhibit the same 
order of affinity, which suggests that the dif- 
ference in the neutralizing activity is not due to the 
difference in their binding ability, but rather to the 
difference in the recognition sites of these mAbs on 
the IL-2 molecule. 
We followed up these observations by Scatchard 
analyses of IL-2 binding in the presence or absence 
of each mAb (fig.3). L15, L20, and L34 inhibited 
high-affinity binding at a concentration of 
100 pug/ml. Few effects were observed on the low- 
affinity binding. L61 inhibited high-affinity 
binding even at a concentration of 1 pg/ml. At 10 
and lOOpg/ml, L61 completely blocked the high- 
affinity binding and slightly reduced the affinity of 
the low-affinity binding. On the other hand, L23 
did not affect both affinity bindings at 1 and 
10 pg/ml, but completely blocked the low-affinity 
binding and reduced the affinity of the high- 
affinity binding at lOO,ug/ml. Control mouse im- 
munoglobulin was without effect up to 100 gg/ml. 
The high-affinity IL-2R is thought to consist of 
the ternary complex of IL-2, ~55, and ~70175 
[g-13], and the p70/75 IL-2R subunit is generally 
thought to be necessary for the biological action of 
IL-2. The binding site(s) on the IL-2 molecule to 
these receptor subunits, however, is still 
speculative at present, and whether the same or 
different site is responsible for the binding has not 
been clarified. The present study clearly shows that 
high- and low-affinity binding sites exist in dif- 
ferent regions on the IL-2 molecule. mAb L61 
recognizes the high-affinity binding site of IL-2, 
thereby inhibiting binding of IL-2 to the high- 
affinity receptor complex (p55-p70/75) and to the 
intermediate-affinity receptor (p70/75), resulting 
in the inhibition of growth of CTLL-2 cells. On the 
Bound IL-2 (Molecules X 10-4Cell) 
Fig.3. Scatchard plots of IL-2 binding to CTLL-2 (2 x ld cells/tube). Serial dilutions of [“sI]IL-2 were preincubated for 1 h at 4°C 
without (0) or with mAb at concentrations of 1 &ml (o), lOpg/ml (A), and NO&ml (m), followed by IL-2 binding assay as 
described in section 2. 
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other hand, L23 recognizes low-affinity binding 
site of IL-2 and inhibits the binding of IL-2 to the 
low-affinity receptor subunit (p55). The resulting 
IL-2-L23 immune complex still retains the ability 
to bind to p70/75, but at a reduced affinity since 
it cannot form the ternary complex. The weak in- 
hibitory activity of L23 observed in figs 1 and 2 can 
be ascribed to the decrease in the affinity of IL-2 
to the receptor. The effects of L15, L20, and L34 
appeared to be qualitatively similar to that of L61, 
but a higher concentration was needed to achieve 
the same effect. A plausible explanation would be 
that these mAbs recognize a site close to but dif- 
ferent from that recognized by L61; they bind to 
the high-affinity binding site of the IL-2 molecule 
in such a way as to decrease the affinity to the 
high-affinity receptor complex (p55-~70175). 
Our results demonstrate that anti IL-2 mAbs, 
L15, L20, L23, L34, and L61 recognize separate 
binding sites on the IL-2 molecule which par- 
ticipate in the binding to ~55 and p70/75 subunits 
of the IL-2 receptor. These mAbs are expected to 
offer important clues to the elucidation of these 
binding sites and also_to the investigation of the 
receptor subunits. 
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